US12364738B2ActiveUtilityA1

Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections

Individually held — no corporate assignee on recordPriority: Jun 8, 2016Filed: Jun 2, 2017Granted: Jul 22, 2025
Est. expiryJun 8, 2036(~9.9 yrs left)· nominal 20-yr term from priority
A61K 9/19A61K 9/08A61K 9/0019A61P 31/04Y02A50/30A61K 38/43A61K 31/7036A61L 31/16C12Y 302/01052A61K 31/4709A61L 27/54A61K 45/06A61K 31/407A61L 29/16A61L 2300/404C12Y 302/01004C12Y 301/21001A61K 31/496A61K 38/47A61K 2300/00A61K 38/465A61K 31/545
26
PatentIndex Score
0
Cited by
28
References
1
Claims

Abstract

The present invention relates to a composition comprising at least one enzyme and at least one microbicidal molecule as combination products, for simultaneous use, separated use or use staggered over time, for use in the preventative and/or curative treatment of infections at an implant site, said infections being post-implant infections of mammalian bodies, in particular post-implant infections of the human body.

Claims

exact text as granted — not AI-modified
The invention claimed is: 
     
       1. A method of treatment for post-implantation infections of mammalian bodies, the method comprising:
 administering a therapeutically effective amount of a composition comprising a combination of an enzymatic cocktail of Dispersin B, cellulase, and DNase; and a fluoroquinolone microbicidal molecule, wherein the composition is sterile, and wherein the composition is effective to reduce by at least 1 Log 10 the number of viable bacteria in biofilms formed post-implantation by bacteria species selected from the species group consisting of  Staphylococcus aureus  to a mammalian body following implantation of an implantable medical device, the mammalian body being subject to post-implantation infection by bacteria belonging to the species  Staphylococcus aureus.

Join the waitlist — get patent alerts

Track US12364738B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.